Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Share-based Compensation (2018 - 2025)

10x Genomics (TXG) has disclosed Share-based Compensation for 8 consecutive years, with $25.2 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation fell 22.5% to $25.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $109.1 million through Dec 2025, down 22.47% year-over-year, with the annual reading at $109.1 million for FY2025, 22.47% down from the prior year.
  • Share-based Compensation hit $25.2 million in Q4 2025 for 10x Genomics, roughly flat from $25.3 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $45.7 million in Q2 2023 to a low of $16.2 million in Q1 2021.
  • Historically, Share-based Compensation has averaged $32.5 million across 5 years, with a median of $33.0 million in 2022.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 140.79% in 2021 and later dropped 28.4% in 2025.
  • Year by year, Share-based Compensation stood at $26.9 million in 2021, then skyrocketed by 52.3% to $41.0 million in 2022, then dropped by 5.02% to $38.9 million in 2023, then dropped by 16.39% to $32.5 million in 2024, then decreased by 22.5% to $25.2 million in 2025.
  • Business Quant data shows Share-based Compensation for TXG at $25.2 million in Q4 2025, $25.3 million in Q3 2025, and $27.6 million in Q2 2025.